Skip Navigation
 
 
 
 xxx
 
Print This Page
Share this page: More
 

Clinical Trials (Experimental Drug studies)

Paraflu Study

Purpose: The Clinical Core has initiated a pilot study of 2 novel FDA approved compounds, fluconazole and paroxetine, for the treatment of HIV-associated neurocognitive disorders (HAND), which show significant neuroprotection in our in vitro model system and also a potent anti-inflammatory effect in our SIV Model.

Contact: 443-799-7241

NIH Study Report


Neurologic AIDS Research Consortium – 1) International Project - HIV Dementia in Uganda: Response to Highly Active Antiretroviral Therapy – Leadership Award

The major goal of this project is to determine whether highly active antiretroviral therapy improves neuropsychological test performance among HIV+ individuals in Uganda with cognitive impairment.

 

The Johns Hopkins NIMH Center newsletter

Clinical Perspectives

HANSA 2011 Presentations

View a presentation by Dr Justin McArthur entitled "NeuroAIDS Research Needs in the Era of HAART."
Learn more.

Out-of-State and International Patients - Find Out More

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.